Tags

Type your tag names separated by a space and hit enter

Distinctive features of severe SARS-CoV-2 pneumonia.
J Clin Invest. 2021 07 15; 131(14)JCI

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is among the most important public health crises of our generation. Despite the promise of prevention offered by effective vaccines, patients with severe COVID-19 will continue to populate hospitals and intensive care units for the foreseeable future. The most common clinical presentation of severe COVID-19 is hypoxemia and respiratory failure, typical of the acute respiratory distress syndrome (ARDS). Whether the clinical features and pathobiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia differ from those of pneumonia secondary to other pathogens is unclear. This uncertainty has created variability in the application of historically proven therapies for ARDS to patients with COVID-19. We review the available literature and find many similarities between patients with ARDS from pneumonia attributable to SARS-CoV-2 versus other respiratory pathogens. A notable exception is the long duration of illness among patients with COVID-19, which could result from its unique pathobiology. Available data support the use of care pathways and therapies proven effective for patients with ARDS, while pointing to unique features that might be therapeutically targeted for patients with severe SARS-CoV-2 pneumonia.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34263736

Citation

Budinger, G R Scott, et al. "Distinctive Features of Severe SARS-CoV-2 Pneumonia." The Journal of Clinical Investigation, vol. 131, no. 14, 2021.
Budinger GRS, Misharin AV, Ridge KM, et al. Distinctive features of severe SARS-CoV-2 pneumonia. J Clin Invest. 2021;131(14).
Budinger, G. R. S., Misharin, A. V., Ridge, K. M., Singer, B. D., & Wunderink, R. G. (2021). Distinctive features of severe SARS-CoV-2 pneumonia. The Journal of Clinical Investigation, 131(14). https://doi.org/10.1172/JCI149412
Budinger GRS, et al. Distinctive Features of Severe SARS-CoV-2 Pneumonia. J Clin Invest. 2021 07 15;131(14) PubMed PMID: 34263736.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Distinctive features of severe SARS-CoV-2 pneumonia. AU - Budinger,G R Scott, AU - Misharin,Alexander V, AU - Ridge,Karen M, AU - Singer,Benjamin D, AU - Wunderink,Richard G, PY - 2022/07/15/pmc-release PY - 2021/7/15/entrez PY - 2021/7/16/pubmed PY - 2021/7/23/medline JF - The Journal of clinical investigation JO - J Clin Invest VL - 131 IS - 14 N2 - The coronavirus disease 2019 (COVID-19) pandemic is among the most important public health crises of our generation. Despite the promise of prevention offered by effective vaccines, patients with severe COVID-19 will continue to populate hospitals and intensive care units for the foreseeable future. The most common clinical presentation of severe COVID-19 is hypoxemia and respiratory failure, typical of the acute respiratory distress syndrome (ARDS). Whether the clinical features and pathobiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia differ from those of pneumonia secondary to other pathogens is unclear. This uncertainty has created variability in the application of historically proven therapies for ARDS to patients with COVID-19. We review the available literature and find many similarities between patients with ARDS from pneumonia attributable to SARS-CoV-2 versus other respiratory pathogens. A notable exception is the long duration of illness among patients with COVID-19, which could result from its unique pathobiology. Available data support the use of care pathways and therapies proven effective for patients with ARDS, while pointing to unique features that might be therapeutically targeted for patients with severe SARS-CoV-2 pneumonia. SN - 1558-8238 UR - https://www.unboundmedicine.com/medline/citation/34263736/Distinctive_features_of_severe_SARS_CoV_2_pneumonia_ DB - PRIME DP - Unbound Medicine ER -